Our study illustrated the correlation of expression level and genomic alternation of CCNA2 with tumor staging, progression, tumor immunity, and drug sensitivity across pancancer and subtypes, especially in ccRCC. This evidence concerns the gene CCNA2 and nonpapillary renal cell carcinoma.